about
Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Genetic polymorphisms in the immune response: A focus on kidney transplantation.Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses.Corrigendum to "Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses" [Pharm. Res. 101 (November) (2015) 124-129].Default Mode Network, Meditation, and Age-Associated Brain Changes: What Can We Learn from the Impact of Mental Training on Well-Being as a Psychotherapeutic Approach?Corneal endothelial cell loss associated to phacoemulsification and ophthalmologist experience: prospective analysis of individual secondary data
P50
Q38276429-C02E664C-BCEF-4B48-A1D4-9A5F6560CAF1Q38546703-4CD923D5-0AA2-4FD8-A4E1-26537E8A71AEQ40830434-DE7325CC-8182-48B3-9A11-0C0B38998E3DQ47918246-CC107A67-5D81-4410-AC37-E6AB036A1562Q53202537-B1A0E955-3FB1-48C7-BBEC-8E6694269008Q64086425-564DF722-4957-4763-B747-A70D349B9099Q90212953-A778F16F-1EE9-467A-8495-449D31B3CDCA
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Jana Stojanova
@en
Jana Stojanova
@nl
type
label
Jana Stojanova
@en
Jana Stojanova
@nl
prefLabel
Jana Stojanova
@en
Jana Stojanova
@nl
P31
P496
0000-0003-4812-5745